• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Cancer Care Grand Rounds

Article

A persistent health-care myth is that the U.S. system is uniquely wasteful versus the European countries that spend far less per patient as a result of tight government control. Only the establishment experts who spread this myth will be surprised, but new research shows American patients are often getting more value—better outcomes and longer lives—in return for those extra dollars.

Read the full story: http://hcp.lv/IFl2JC

Source: The Wall Street Journal

Related Videos
Dr Susan Vadaparampil
Dr Ameet Patel
A new study finds law enforcement presence in emergency departments may disrupt care. Lead author Prashasti Bhatnagar discusses policy and training solutions.
Jennifer Snow, MPA, NAMI
Jennifer Snow, MPA, NAMI
Dr Debra Patt
Most employees are unprepared to shop for coverage on their own, underscoring the need for stronger decision tools and consumer protections.
Experts warn that ICHRAs could either stabilize or destabilize the individual market, depending on which workers employers shift into these plans.
Dr Eric Yang
Danielle Roman, PharmD, BCOP, Allgheny Health Network
Related Content
Drug pricing | Image Credit: © TarikVision-stock.adobe.com

TrumpRx Launch Brings Savings—and Uncertainty

February 5th 2026
Article

First announced in September 2025, the online platform is set to offer access to prescription medications at steep discounts, with potential savings in the millions.

Read More

Managed Care Cast Square Image

The Orphan Drug Act in the Modern Drug Pricing Era

February 3rd 2026
Podcast

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Listen

Insulin syringe | Image Credit: © ixel-Shot-stock.adobe.com

Express Scripts Avoids Fines but Agrees to Major Structural Overhaul

February 5th 2026
Article

The FTC first sued Express Scripts, CVS Caremark, and Optum in 2024, claiming anticompetitive and unfair rebating practices surrounding insulin.

Read More

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

January 20th 2026
Podcast

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

Prescription drugs on a money banknotes. Concept of healthcare costs - Vitalii - stock.adobe.com.jpeg

Senate Democrats Outline Drug Pricing Agenda to Cut Patient Costs

February 4th 2026
Article

Finance Committee leaders propose expanding Medicare negotiation, curbing middlemen, and reinvesting in biomedical innovation as part of a 2026 health care affordability strategy.

Read More

Jesse Dresser, Esq

New Regulations on PBMs Become Law: What This Means for Pharmacies Nationwide—A Q&A With Jesse Dresser, Esq

February 4th 2026
Article

The Consolidated Appropriations Act of 2026 features new language that could change the way that pharmacy benefit managers (PBMs) operate in the US.

Read More

© 2026 MJH Life Sciences
AJMC®
All rights reserved.